Dokumente
Suchschritt : FT=glucosamine AND FT=osteoarthritis
» Fenster schließen »

2/216 von 416 DIMDI: MEDLINE (ME60) © NLM

ND: | ME12405690
PMID: | 12405690
LR: | 20061115
CED: | 20021030
DCO: | 20030226
Autoren: | Fenton JI; Chlebek-Brown KA; Caron JP; Orth MW
Titel: | Effect of glucosamine on interleukin-1-conditioned articular cartilage.
Quelle: | Equine veterinary journal. Supplement (34); p. 219-23 /200209/
PM: | Print
SU: | IM
Sprache: | English
CY: | England
JID: | 9614088
Institution: | Department of Animal Science, Michigan State University, East Lansing 48824, USA.
DT: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
Schlagwörter
CT: | ANIMALS; CARTILAGE, ARTICULAR/*drug effects; CARTILAGE, ARTICULAR/metabolism; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSAMINE/*pharmacology; GLUCOSAMINE/therapeutic use; HORSE DISEASES/*drug therapy; HORSE DISEASES/metabolism; HORSES; INTERLEUKIN-1/pharmacology; MATRIX METALLOPROTEINASE 3/antagonists & inhibitors; MATRIX METALLOPROTEINASE 3/drug effects; MATRIX METALLOPROTEINASE 3/metabolism; MATRIX METALLOPROTEINASES/drug effects; MATRIX METALLOPROTEINASES/metabolism; NITRIC OXIDE/biosynthesis; OSTEOARTHRITIS/drug therapy; OSTEOARTHRITIS/metabolism; OSTEOARTHRITIS/*veterinary
CTG: | TIER; KNORPEL, GELENK-/*Arzneimittelwirkungen; KNORPEL, GELENK-/Stoffwechsel; ZELLEN, KULTIVIERTE; DOSIS-WIRKUNGSBEZIEHUNG, ARZNEIMITTEL-; GLUCOSAMIN/*Pharmakologie; GLUCOSAMIN/therapeutische Anwendung; PFERDEKRANKHEITEN/*Arzneimitteltherapie; PFERDEKRANKHEITEN/Stoffwechsel; PFERDE; INTERLEUKIN-1/Pharmakologie; STROMELYSIN 1/Antagonisten & Inhibitoren; STROMELYSIN 1/Arzneimittelwirkungen; STROMELYSIN 1/Stoffwechsel; MATRIX-METALLOPROTEINASEN/Arzneimittelwirkungen; MATRIX-METALLOPROTEINASEN/Stoffwechsel; STICKSTOFFMONOXID/Biosynthese; OSTEOARTHROSE/Arzneimitteltherapie; OSTEOARTHROSE/Stoffwechsel; OSTEOARTHROSE/*Veterinärmedizin
TE: | Interleukin-1; Nitric Oxide/10102-43-9; Glucosamine/3416-24-8; Matrix Metalloproteinases/E.C. 3.4.24.-; Matrix Metalloproteinase 3/E.C. 3.4.24.17
CR: | 10102-43-9; 3416-24-8; E.C. 3.4.24.-; E.C. 3.4.24.17
AB: | Glucosamine inhibits recombinant human interleukin-1 stimulated cartilage degradation in equine cartilage explants. Recently, recombinant equine interleukin-1 has been cloned and purified. Therefore, the objective of this study was to characterise the effects of glucosamine on indices of cartilage degradation in recombinant equine IL-1beta-stimulated equine articular cartilage explants. Cartilage discs were harvested from the weight-bearing region of the articular surface of the antebrachiocarpal and middle carpal joints of horses (age 2-8 years) and cultured under standard conditions. Explants were exposed to recombinant equine interleukin-1beta (reIL-1beta) on Days 1-4 in the presence or absence of glucosamine (0.25, 2.5 or 25 mg/ml), with appropriate controls. Nitric oxide, prostaglandin E2, sulphated proteoglycan, stromelysin and gelatinase/collagenase activity released into conditioned media and total tissue proteoglycan content were measured as indicators of cartilage catabolism. Glucosamine inhibited cartilage catabolic responses in a dose dependent manner that was statistically significant at a dose of 0.25 mg/ml for stromelysin activity and 2.5 mg/ml for collagenase/gelatinase activity. At 25 mg/ml glucosamine also prevented IL-1beta-induced increases in nitric oxide production, prostaglandin E2 and proteoglycan release to media. Glucosamine prevents equine articular cartilage degradation experimentally induced by reIL-1beta in vitro. These data provide further support for the use of glucosamine in treatment or prevention of cartilage loss in athletic horses.

» Volltext »
» Fenster schließen »